Aug 30 2024 This Week in Cardiology

Aug 30, 2024

Dr. John Mandrola, a prominent cardiologist, shares insights from the European Society of Cardiology meeting. He discusses the implications of beta blockers post-myocardial infarction and introduces a promising new therapy for ATTR cardiomyopathy. Mandrola also highlights the importance of temporarily halting RAS inhibitors before non-cardiac surgery and presents encouraging developments in managing heart failure with preserved ejection fraction. The episode further examines the significance of placebo effects in cardiology trials and their influence on patient quality of life.

Ask episode

Chapters

Transcript

Episode notes

Latest Advances in Cardiovascular Research

00:00 • 24min

Exploring Placebo Effects in Cardiology Trials

24:19 • 2min

From ESC: post-MI beta blockers, a new therapy for ATTR-CM, holding RASi before non-cardiac surgery, good news in HFpEF, and an ESC preview are the topics John Mandrola, MD, covers this week.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. ABYSS

ABYSS trial https://www.nejm.org/doi/full/10.1056/NEJMoa2404204
REDUCE AMI https://www.nejm.org/doi/full/10.1056/NEJMoa2401479

II. ATTR -CM HELIOS B

Positive Top Line Results for Vutrisiran in Cardiac Amyloidosis

https://www.medscape.com/viewarticle/positive-top-line-results-vutrisiran-cardiac-amyloidosis-2024a1000cjj

HELIOS A https://www.tandfonline.com/doi/full/10.1080/13506129.2022.2091985
HELIOS B https://www.nejm.org/doi/full/10.1056/NEJMoa2409134

III. STOP or NOT Trial

Observational Study Showing Benefits of Holding RASi https://doi.org/10.1097/ALN.0000000000001404
STOP or NOT Protocol Paper -- https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-019-3247-1
JAMA STOP or NOT https://jamanetwork.com/journals/jama/fullarticle/2823118

IV. GLP1a in HFpEF

The GLP-1 Agonist Semaglutide in HFpEF Cleared a Low Bar https://www.medscape.com/viewarticle/995872

STEP-HFpEF https://www.nejm.org/doi/full/10.1056/NEJMoa2306963
STEP-HFpEF-DM https://www.nejm.org/doi/full/10.1056/NEJMoa2313917
SELECT https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
FLOW https://www.nejm.org/doi/full/10.1056/NEJMoa2403347
Lancet Meta-analysis https://doi.org/10.1016/S0140-6736(24)01643-X

V. ESC Preview

Mandrola's Five Big Trials to Look for at ESC 2024

https://www.medscape.com/viewarticle/mandrolas-five-big-trials-look-esc-2024-2024a1000fkt

Topline Finerenone Results Point to Advance in Heart Failure

https://www.medscape.com/viewarticle/topline-finerenone-results-point-advance-heart-failure-2024a1000fq2

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net